Monitoring the safety of licensed medicines

Nature Reviews Drug Discovery

Volumn 4, Issue 7, 2005, Pages 541-543

  Breckenridge, Alasdair ^a   Woods, Kent ^a   Raine, June ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CYCLOOXYGENASE 2 INHIBITOR; DOSULEPIN; FLUOXETINE; PAROXETINE; ROFECOXIB;

ARTICLE; AUTOMUTILATION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; LICENSING; MANAGEMENT; MANDATORY REPORTING; MEDICAL RECORD; PRIORITY JOURNAL; SUICIDAL BEHAVIOR; SYSTEM ANALYSIS;

DATABASES, FACTUAL; GREAT BRITAIN; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES;

EID: 22144495375     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1778     Document Type: Article

References (13)

1. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709-1711 (2004).
2. Topol, E. J. Failing public health - rofecoxib, Merck and the FDA. N. Engl. J. Med. 351, 1707-1709 (2004).
3. Frantz, S. How to avoid another 'Vioxx'. Nature Rev. Drug Discov. 4, 5-7 (2005).
4. Belton, K. J. and the European Pharmacovigilance Research Group Attitude survey of adverse drug reaction reporting by health care professionals across the European Union. Eur. J. Clin. Pharmacol. 6, 423-427 (1997).
5. Mann, R. D. Prescription Event Monitoring - recent progress and future horizons. Br. J. Clin. Pharmacol. 46, 195-201 (1998).
6. Safety Assessment of Marketed Medicines. Guidelines for company sponsored safety assessment of marketed medicines. (London MCA, 1993).
7. Griffin, M. R., Stein, M. S. & Ray, W. A. Post marketing surveillance for drug safety; surely we can do better. Clin. Pharmacol. Ther. 75, 491-494 (2004)
8. Report of the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 45, 2004).
9. Jick, H., Kaye, J. & Jick, S. Antidepressants and the risk of suicidal behaviours. JAMA 292, 338-343 (2004)
10. Glaxo SmithKline. Report quoted in the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 103-104, 2004).
11. Martinez, C. et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case control study. Br. Med. J. 330, 389 (2005).
12. Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
13. Rubenstein, S. How best to monitor drugs after they're FDA approved. Q&A Wall Street Journal (20 Dec 2004).